Fig. 3

UM171a treatment leads to ROS production. A A heatmap showing differentially expressed genes in GO:0019883 (Antigen processing and presentation). This process is substantially up-regulated in UM171a 72 h treated group [normalized enrichment score = 2.1; FDR < 0.01]. B Transcript quantification of genes involved in the ERAD pathway. C Representative MitoSOX staining of MSCs or MEFs treated with UM171a. The dashed line represents the signal for the DMSO/MitoSOX condition. D Representative experiment of MitoSOX staining of UM171a-treated MSCs following antioxidant treatment. The dashed line represents the UM171a MitoSOX signal. E Antigen cross-presentation assay using the antioxidants MitoTEMPO (10 μM), α-tocopherol (800 μM), and NAC (5 mM) added at day 0 with UM171a for 72 h. Red arrows highlight the inhibitory effect of the antioxidants on antigen cross-presentation. F Quantification of Psmb8 transcript in UM171a-treated MSCs undergoing co-treatment with antioxidants over 72 h. The UM171a group (positive control) is displayed in red. For panels B, E and F, n = 6/group with *P < 0.05, **P < 0.01 and ***P < 0.001